Tuesday, July 14, 2026

 

Research highlights concussion challenges for athletes with ADHD



UM, Southern Miss researchers hope to improve concussion diagnosis, recovery and return-to-play decisions




University of Mississippi





New research from the University of Mississippi indicates that athletes with ADHD need even more scrutiny when head injuries are involved.

Athletics trainers, coaches and doctors have focused a lot of attention on detecting concussions among athletes and ensuring they have time to heal after suffering one.

Athletes with attention-deficit/hyperactivity disorder are more susceptible to concussions and have a longer recovery period, said Corbit Franks, assistant professor and clinical education coordinator for athletic training at the University of Mississippi. He collaborated on a literature study with Jeffrey Parr and Mary King, both of the University of Southern Mississippi.

"Our purpose was to bring together high-quality peer reviewed research into one singular review paper for clinicians, coaches and athletes and also see how much ADHD actually does affect the risk, the assessment and the recovery of concussion," Franks said.

For Franks and Parr, the research is personal. Franks was diagnosed with ADHD as a child, and Parr's stepson also has it.

"I've had ADHD my entire life and doing concussion testing wasn't really a thing when I was playing baseball and football while growing up in Tennessee," Franks said. "What we called back then, 'getting your bell rung,' I know now I had several concussions playing, but they were never assessed or diagnosed or anything else."

When Parr's stepson hit his head, some obstacles arose.

"My stepson has ADHD, and I noticed several of the symptoms he dealt with on a daily basis overlapped with what we see in sport-related concussions," Parr said. "Then when he fell and hit his head, I realized how difficult it was to differentiate between his normal ADHD symptoms and what we would consider concussion related symptoms."

The overlapping symptoms shared between ADHD and concussions include fatigue and sleep imbalances, emotional irregularity and difficulty focusing. Therefore, when an athlete with ADHD is concussed, it becomes difficult to determine which symptom belongs to which condition, as Parr and his stepson experienced.

ADHD affects 4.2 to 8.1% of young athletes. Evidence from the study indicates that athletes with ADHD may:

  • Be 1.6 to 2.5 times more likely to sustain a concussion, possibly due to impulsivity and risk-taking behaviors
  • Report more severe or prolonged post-concussion symptoms
  • Experience differences in baseline neurocognitive testing, or pre-concussion testing, which can complicate concussion diagnosis and management.

Whether an athlete has suffered a concussion can be assessed in several ways, ranging from a series of questions and actions on the sideline to a computer test or an app on a handheld electronic device.

When Franks began administering concussion tests as an athletic trainer, he experienced what it was like for ADHD athletes.

"I would take the test just to make sure I understood what it entailed, to be able to explain it to coaches, parents and athletes, and I always struggled on those tests staying focused," he said.

"So when athletes would come in and they had ADHD, it helped me understand that taking this test for them on a computer is not going to look the same as the athlete that maintains their attention all the time."

The baseline concussion test results for an athlete with ADHD may not be accurate, causing them to be over- or underdiagnosed. This can hinder their care once a concussion occurs.

The study found that athletes with ADHD take four to six days longer to recover from a concussion, Franks said.

What comes next is trying to understand why athletes with ADHD have a longer time until they return to learning and return to sport.

"Return-to-learn strategies and return-to-play protocols may need to look completely different for that sector of individuals, rather than our traditional way we've all done things," Franks said.

Just as athletes are becoming more specialized and individualized in their training, including nutrition, training and psychology, concussion diagnosis and treatment should consider following suit, the Ole Miss professor said.

"When you look at athletics in general, for the last several years, we've started to attempt to treat athletes more as individuals, whether that's through mental health, counseling, their nutritional strategies, their performance strategies, strength conditioning, so why are we not looking at concussions more as an individualized thing?" Franks said.

"With ADHD individuals, it pushes further this idea that just like with learning or anything else, we don't fall into the normal box. So, we have to look at routes to implement different strategies for the diagnosis and the management of concussions and ADHD individuals."

Considering an athlete's ADHD plays an essential role in that individualized plan.

"Recognizing ADHD as a modifier can lead to more accurate diagnoses, better symptom interpretation and safer return-to-play decisions," Parr said. "It also highlights the need for athletic trainers to be particularly aware of which athletes have an ADHD diagnosis."

 

What is a bio-metal? exploring the metallic mystery of an ancient maw



Studies of ancient sea worms reveal a type of material that is not quite metal nor biological.




American Institute of Physics

Cross-section of a bristle worm jaw sample 

image: 

A cross-section of a bristle worm jaw sample with the indentation testing sites labeled 1 to 11.

view more 

Credit: Zelaya-Lainez et al.





WASHINGTON, July 14, 2026 — When playing the classic game “20 Questions,” one may begin with the common opener: “Animal, vegetable, or mineral?”

For the ancient sea worm Perinereis cultrifera (which is still around to this day), the answer might not be so simple. Along with other predatory bristle worms, Perinereis cultrifera have jaws made from structural proteins and ions, which are used for eating, crushing, or biting. The unique makeup and properties of these jaws led some researchers to coin a new term to describe these types of materials: bio-metals, an emerging field of biophysical studies.

The term “bio-metal” goes beyond identifiers like “metallike biomaterials” or “biomaterials with metallike properties,” which have been used in scientific literature to describe biomaterials with conductivity or strength values similar to metals. Instead, bio-metals can be categorized by three qualities: hardness, strain mechanics, and ion-protein structure.

In Biophysics Reviews, by AIP Publishing, researchers from TU Wien (Vienna University of Technology) and the University of Vienna examined the metallic qualities of the sea worm to further define the new classification.

The researchers began by studying hardness through nanoindentation — in which researchers create microscopic indents in a material — accompanied by chemical analysis and imaging. Confirming earlier studies, they showed that the concentration of metal ions is higher at the tips of the jaw than at the center, likely leading to the increased hardness of the tips.

Then, they probed the jaw with different indentation depths, and surprisingly, discovered a phenomenon seen in metals such as copper or silver, known as the Nix-Gao nanoindentation size effect: Smaller regions of the worm jaw were harder to dent due to the larger spatial change of strain levels. This causes increased interlocking of fractures in the atomic structure and is a hallmark of the size effect.

Despite these similarities, bio-metals are still unique in their mechanical properties.

“Bristle worm jaws also showed size-dependent elasticity — this is a distinguishing feature of bio-metals when compared to standard crystalline metals like copper or silver,” said author Christian Hellmich.

Finally, the researchers theoretically explained these elastic size effects through mathematical modeling of what’s happening at the atomic level. Hellmich said they are only scratching the surface of this research — pun intended.

“We plan to extend the experimental database by investigating additional species to refine the theoretical concept and perform dedicated computations, and — perhaps most interestingly — to explore the link between genetic interventions and the corresponding material design space,” he said. “All this comes with true excitement about the beauty, elegance, and refinement found in and produced by nature.”

###

The article “‘Bio-metals’: Ancient biological materials with nanoindentation size effects: Experiments and elements of manifold micromechanics” is authored by Luis Zelaya-Lainez, Friedrich S. Schuster, Stefan Manhartseder, Maximilian Landegger, Kyojiro N. Ikeda, Florian Raible, Olaf Lahayne, Stefan Scheiner, and Christian Hellmich. It will appear in Biophysics Reviews on July 14, 2026 (DOI: 10.1063/5.0325367). After that date, it can be accessed at https://doi.org/10.1063/5.0325367.

ABOUT THE JOURNAL

Biophysics Reviews publishes research studies and comprehensive review articles of new and emerging areas of interest to the biophysics community. The journal’s focus includes experimental and theoretical research of fundamental issues in biophysics in addition to the application of biophysics in other branches of science, medicine, and engineering. See https://pubs.aip.org/aip/bpr.

###

 

Six medical societies call for immediate adoption of enhanced radiation protection in fluoroscopy labs



New multi-society expert consensus statement says safer technologies are available now and should become the standard for protecting healthcare workers



Society for Cardiovascular Angiography and Interventions






WASHINGTON—Healthcare professionals performing minimally invasive procedures in fluoroscopy laboratories, often called “cath labs,” should no longer have to accept preventable radiation exposure and orthopedic injuries as part of their jobs, according to an expert consensus statement released today that is endorsed by six leading medical societies. 

Published today in JSCAI, the Journal of Vascular and Interventional Radiology (JVIR), and JACC: Cardiovascular Interventions, “SCAI/ASE/HRS/SIR/SVS Expert Consensus Statement on Enhanced Radiation Protection: Time for Mandatory and Urgent Action” calls for hospitals, manufacturers, regulators, and professional societies to immediately adopt enhanced radiation protection technologies, modernize radiation safety standards, and strengthen monitoring and reporting practices to better protect the healthcare teams working in fluoroscopy laboratories. 

Given the availability of safer technologies, the authors say broader implementation of enhanced radiation protection devices (ERPDs) is both an ethical responsibility and a necessary evolution of ALARA (“As Low As Reasonably Achievable”), the longstanding radiation safety standard that exposures should be kept “as low as reasonably achievable.” 

“For decades, we accepted occupational radiation exposure and the physical burden of heavy protective equipment as unavoidable realities of working in a fluoroscopy laboratory,” said David G. Rizik, MD, MSCAI, chair of the writing group. “That is no longer acceptable. Technologies available today can greatly reduce radiation exposure while also addressing the orthopedic injuries associated with traditional lead protection. The question is no longer whether these solutions exist. It is whether we are willing to make protecting healthcare workers the priority it deserves. This consensus makes clear that the time for implementation is now.” 

ERPDs reduce radiation exposure through engineering controls rather than relying primarily on personal protective equipment. The consensus statement cites evidence that ERPDs can reduce operator and staff radiation exposure by up to 99 percent. 

The statement cited a 2023 SCAI survey of interventional cardiologists, which found that nearly 60 percent reported orthopedic injuries and 17 percent reported limiting their time in the cath lab to reduce radiation exposure. Among women respondents, 28 percent reported being discouraged from working in the cath lab because of pregnancy or considering pregnancy, while 71 percent wanted the option to step away from the cath lab during pregnancy. 

“Every clinician and staff member who leaves the fluoroscopy laboratory because of preventable injury or chronic occupational disease represents a loss of expertise that patients depend on, in addition to the immense pain and loss experienced by the clinician and their loved ones,” said James B. Hermiller, MD, MSCAI, cochair of the writing group. “Demand for minimally invasive procedures continues to grow, and the duration and complexity of these procedures are increasing. Maintaining a healthy, experienced workforce will be essential to ensuring patients continue to have access to the lifesaving care these teams provide.”  

The statement calls for healthcare organizations and policymakers to: 

  • Share responsibility among healthcare institutions, manufacturers, regulators, and professional societies for improving occupational safety in fluoroscopy laboratories. 
  • Adopt ERPDs that can dramatically reduce occupational radiation exposure for physicians and staff. 
  • Modernize federal and state radiation safety regulations to reflect today’s technology and evidence. 
  • Measure and report radiation safety performance using real-time dosimetry and standardized quality metrics. 
  • Design safer fluoroscopy laboratories by integrating enhanced radiation protection into imaging systems and procedure rooms instead of relying primarily on heavy wearable lead. 
  • Expand education, training, and research to accelerate implementation and continuous improvement. 

“Our goal is to ensure the best outcomes for patients as well as for the healthcare team that is operating within the fluoroscopy lab. Today’s enhanced radiation protection systems give us a clear opportunity to align policy, technology, and clinical practice around a safer standard. From healthcare systems to manufacturers, state legislatures and regulators, we all have a role in making sure these protections become part of the infrastructure used to deliver interventional care. This will ensure continued growth and access for these essential procedures,” said SCAI President J. Dawn Abbott, MD, MSCAI

The multisociety expert consensus statement is endorsed by the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), the American Society of Echocardiography (ASE), the Heart Rhythm Society (HRS), the Society of Interventional Radiology (SIR), and the Society for Vascular Surgery (SVS). 

 

About the Society for Cardiovascular Angiography & Interventions (SCAI) 

The Society for Cardiovascular Angiography & Interventions, established in 1978, stands as the primary nonprofit medical society dedicated to representing invasive and interventional cardiology. SCAI's mission is to guide the global interventional cardiovascular community by fostering education, advocacy, research, and upholding standards for quality patient care. For more than 40 years, SCAI has exemplified professional excellence and innovation worldwide, cultivating a reputable community of over 5,000 members committed to advancing medical science and providing life-saving care for individuals, both adults and children, affected by cardiovascular disease.  For more information, visit www.scai.org.

 

3D-printed contact lenses for your eyes only in just 20 minutes


University of Waterloo platform paves the way for patient-specific lenses in a single visit to the optometrist



University of Waterloo

3D-printed contact lens 

image: 

A close-up of the 3D-printed contact lens on the printing platform in University of Waterloo’s Tang Nanotechnology Lab. 

view more 

Credit: (Jay Mielke/University of Waterloo)





A breakthrough combination of new silicone materials and advanced 3D printing technology developed by University of Waterloo researchers could transform how contact lenses are manufactured.   

The award-winning innovation can produce patient-specific contact lenses in as little as 20 minutes, paving the way for specialized lenses to be designed, manufactured and dispensed during a single visit to the optometrist.   

Most contact lenses are manufactured in a limited range of sizes and shapes rather than being custom-made for each person's eye. While soft lenses are suitable for many wearers, patients with irregularly shaped corneas often require rigid lenses to achieve clear vision. Finding the right fit can require several appointments over weeks or months before patients receive lenses that fit properly and provide the function they need.  

Researchers in Waterloo’s Department of Chemistry developed the digital manufacturing platform to address these challenges.  

"We are very excited about this work because it brings us closer to contact lenses that are truly personalized," said Dr. Shirley Tang, professor in Waterloo’s Department of Chemistry. "Our technology produces lenses with patient-specific surfaces for a precise fit while delivering the optical clarity and mechanical performance expected of commercial contact lenses.”  

The platform combines custom lens design software, a newly developed silicone material, and advanced manufacturing techniques.  

Silicone is widely used in contact lenses because it is safe, biocompatible and highly oxygen permeable. However, conventional silicone materials are generally not compatible with 3D printing. To overcome this barrier, the Waterloo team developed a new hydrophilic silicone formulation specifically designed for additive manufacturing while maintaining the properties required for contact lens applications.  

"Our software designs a lens with an inner surface that precisely matches the patient's cornea and an outer surface that provides the required vision correction," said Dr. Sayan Ganguly, Chemistry research associate at Waterloo. "The novel hydrophilic silicone material we created, combined with our manufacturing process, produces smooth, transparent lenses that are comfortable to wear."  

Because 3D-printed objects are built layer by layer, tiny stair-step imperfections can form on curved surfaces and reduce optical clarity and wearer comfort. To address this issue, the team developed an ultra-thin, non-contact coating process that smooths the surface without altering the customized shape of the lens or compromising its optical performance.  

Laboratory testing confirmed the lenses are biocompatible and the team is preparing for in vivo studies. Researchers have filed a provisional patent for the hydrophilic silicone material and are preparing a full patent application.  

Working with the Centre for Vision and Eye Research (CEVR), a joint research institute of the University of Waterloo and the Hong Kong Polytechnic University, the researchers are advancing the technology toward commercialization.   

The project recently received a Gold Medal at the Shanghai International Exhibition of Inventions in June 2026.  

The study, "Patient-specific hard contact lenses fabricated by vat photopolymerization printing and non-contact fluidization coating," was recently published in Materials & Design

 

Plant-based wound dressing fights infection before it takes hold



University of Bat





A new dressing made from plant-based materials can deliver antibiotics directly to wounds during critical early stages of infection, according to researchers from the University of Bath. The study, published in Bioactive Materials, is the first to use this family of sustainable furan-based polymers, previously explored for sustainable plastics and packaging, for infection-fighting wound dressings.

Wound infections are a major challenge for healthcare systems worldwide and are estimated to cost the NHS alone billions every year. Bacteria can enter a wound and begin forming a protective, slimy layer known as a biofilm within hours, slowing healing and making infections much harder to treat.

The team from the Department of Chemical Engineering and the Department of Chemistry has created a novel, two-sided dressing from sustainable polymers, a plastic-like material sourced from plants, not petrochemicals. One side of the dressing rapidly releases antibiotics into the wound, while the other acts as a barrier to maintain the protected healing environment. 

The novel dressing intervenes in the early window before the biofilm grows, when treatment is most effective. It quickly releases the antibiotic and reaches effective concentrations within four hours, reducing biofilm formation by over 90%.

A two-sided material

Unlike many advanced wound dressings that rely on petroleum-based plastics or additional chemical treatments, this dressing is made simply from two plant-based layers which have different properties. Two types of plant-based polymer are spun into a thin mesh of microscopic fibres. On the wound-facing side, the commonly used antibiotic, tetracycline, is incorporated. The outer side of the dressing repels water to moderate moisture loss and promote healing.

Dr Xiang Ding, the study’s lead author, said: “The two materials we used are very similar chemically; they differ by only two carbon atoms, but by spinning them into ultra-fine fibres, we can amplify these tiny molecular differences into dramatically different behaviours.

“This allowed us to create a smart, two-sided dressing without any additional chemical modification, simultaneously guiding the antibiotic towards the wound while helping to prevent unnecessary loss of the drug away from the injury site and providing a barrier to protect the wound."

Fighting infection-causing bacteria

The multidisciplinary team from Bath, together with collaborators from the University of Bristol and Newcastle University, tested the dressing against two common wound-infecting bacteria, Staphylococcus aureus and Pseudomonas aeruginosa. Results from lab tests using model wounds showed a significant reduction in bacterial growth and biofilm formation after dressing application. The material is also compatible with human skin cells, showing no signs of toxicity in laboratory testing.

The study demonstrates how plant-based materials previously developed for sustainable plastics and packaging applications could be adapted for advanced healthcare technologies. While further development and testing will be needed before any clinical use, the findings highlight the potential for more sustainable wound care technologies without compromising on performance.

ENDS

Notes to editors:

Images are available at: https://tinyurl.com/3dc4p9ec

For more information, please contact Sarah Baker-Gaunt at the University of Bath Press Office on press@bath.ac.uk

 

New cancer drug shows promise in mesothelioma trial



Vermont team controls disease in 67% of patients—by attacking cancer energy system




University of Vermont

University of Vermont Scientists at Cancer Center Lab 

image: 

University of Vermont postdoctoral scientist Victoria Gibson and professor Brian Cunniff working in a lab at UVM’s Cancer Center. They are the lead authors on a new study in the journal Nature Communications that reveals an unexpected and promising way to treat the deadly disease mesothelioma—and perhaps other cancers too. Working with RS Oncology LLC, the UVM team will reveal its stage 2 clinical trial results of their new medicine later this year.

view more 

Credit: Joshua Brown/UVM





Mesothelioma is a rare but aggressive cancer, usually caused by exposure to asbestos. Inhaled asbestos fibers become lodged in the lungs, causing inflammation that can lead to tumor formation decades later. Worldwide, about 30,000 people are diagnosed with mesothelioma each year. Current treatments—immunotherapy and chemotherapy—offer limited benefit. Patients—often men who worked in shipbuilding, oil refining, and asbestos manufacturing—face a median survival of approximately 12 months and a five-year survival rate around 10 percent. 

 "It's a disease of a significant unmet medical need,” says Brian Cunniff, a professor at the University of Vermont.

Now, a study published July 14 in Nature Communications by Cunniff, UVM research scientist Victoria Gibson, and an international team of collaborators reports a counterintuitive new approach to treating the disease—and perhaps other cancers too.

In a “phase one” clinical trial, sponsored by RS Oncology, LLC, people with relapsed mesothelioma were given the new drug and it controlled disease progression in 67% of the patients and in some patients the tumors got smaller. More importantly, the drug was well tolerated and these critically ill patients lived longer than patients given the standard treatments.

Turning Cancer's Own Defenses Against It

Like many cancers, mesothelioma tumors generate elevated levels of “reactive oxygen species”—unstable and damaging molecules that are a byproduct of rapid tumor cell metabolism. To survive under these conditions, tumor cells ramp up production of antioxidant enzymes, including one called peroxiredoxin 3, or PRX3, in the cell’s powerhouses—the mitochondria—that protect tumor cells from these damaging molecules.

The UVM team's insight was to flip the conventional logic of cancer treatment. For years, clinical trials attempted to increase antioxidants to combat cancer, reasoning that lowering reactive oxygen species would slow tumor growth. Those trials largely failed, and some showed that increasing antioxidants promoted tumor growth. The UVM team took the opposite approach: inhibit PRX3, overwhelm the tumor cell with oxidative stress, and kill it.

The trial drug developed by RS Oncology, based on UVM’s discoveries, uses a naturally occurring antibiotic, thiostrepton, to disable PRX3. This causes a buildup of hydrogen peroxide in the mitochondria of tumor cells and triggers their death. Because tumor cells generate more reactive oxygen species than normal cells, PRX3 turns over faster in tumor cells which increases selectivity to cancer cells rather than healthy ones.

When the team deleted PRX3 entirely in mesothelioma tumor cell lines, the results were striking: mitochondrial function decreased, cell proliferation slowed dramatically, and the cancer cells were unable to form tumors in animal tests. Other groups have shown that when PRX3 is knocked out in healthy mice, there were no adverse effects—a finding that addresses a common objection to targeting mitochondria. "People will come up to us at conferences and state that you can't target the mitochondria because they’re too important," said Gibson. "The evidence—that you can knock out PRX3 in mice and there's no adverse phenotype— supports our approach.” In other words, the scientists showed that they could remove the genes for the PRX3 enzyme from developing mice and that the animals functioned normally.  

From the Laboratory to the Clinic

The laboratory foundation for this work was established at UVM’s Cancer Center around 2015. Seeing promising early results with thiostrepton, a team formed RS Oncology, a private pharmaceutical company, to translate UVM findings into the clinic. UVM’s Brian Cunniff—an associate professor in the Department of Pathology and Laboratory Medicine at the university’s Larner College of Medicine—serves as the company’s chief science officer. Eventually, the team developed thiostrepton into a novel clinical formulation called RSO-021 and conducted a phase one clinical trial in the United Kingdom under oversight of the MHRA, the UK equivalent of the FDA, between 2022 and 2023.

The drug is administered directly into the chest through a catheter already in place for patients who have “pleural effusions”—a buildup of fluid between the lung and chest wall that affects approximately 90 percent of mesothelioma patients. This local delivery concentrates the drug at the tumor site while limiting systemic exposure.  

The phase one trial met its requirements for safety and tolerability at a 90-milligram dose, with no patient deaths attributed to the drug. Crucially, the team demonstrated on-target engagement in patient tissue samples—confirming that the drug's mechanism of action, observed in cells and mice in the laboratory, also works in human tumors.

Progression-free survival averaged 4.2 months, comparable to current therapies. More significantly, overall survival in the cohort of 15 patients was better than what is seen with existing treatments—a finding Cunniff describes as a potential “game changer.”

"Our overall survival data is very promising and will hopefully persist with additional patients," Cunniff said.

The team’s data also suggests the new drug may also help awaken the immune system to attack or slow the tumor. "Our drug has both cytotoxic activity, it can kill the tumor cells, but it also has immunomodulatory capacity where it can modulate the immune system to now manage the tumor," said Cunniff.

Phase two of the drug trial has now been completed, and results are expected to be presented at a global oncology meeting this year. 

What Comes Next

The research program is expanding on multiple fronts. The UVM and RS Oncology team, in collaboration with the University of Leicester and other institutions in the UK, are developing second-generation PRX3 inhibitors that are more soluble and potentially deliverable as an oral tablet. This might allow the drug to be brought to market more easily and have application with cancer types beyond mesothelioma. At UVM, Victoria Gibson, the lead author on the new study, is remaining as a postdoctoral researcher to help initiate new research using thiostrepton for peritoneal malignancies, including mesothelioma, gastric cancer, and other gastrointestinal cancers, in collaboration with Conor O’Neill, a surgical oncologist at the UVM Cancer Center and UVM Health. "We believe this mechanism could be applicable to other cancers," Cunniff said.

For Gibson, the work is personal. "I've always just had a desire to help people because I feel like everyone has experienced cancer in their life, whether it's them, friends, or family members," she said. Still, when a family member called the lab hoping to enroll her dying father in the clinical trial, Gibson was caught off guard. "We just work in a lab all day working with cells," she recalled, "and the fact that we're making an impact on people, that they're wanting to be on this clinical trial, just was amazing to me."